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Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116
cells, opposite to its effects on MDA-MB-231 cells
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Abstract: One of the most challenging problems in colorectal cancer (CRC) is resistance to chemotherapy drugs such as doxorubicin
(DOX). The programmed death ligand-1 (PD-L1) is related to chemoresistance and is overexpressed in several human cancer cell types.
Here, we investigated the changes in the expression of PD-L1 in DOX-treated CRC and breast cancer (BRC) cells. Also, to address
PD-L1 regulation, we assessed expression levels of miR-140 and miR-34a, two microRNAs that can target the 3’ UTR region of the
gene encoding PD-L1. HCT116 CRC and MDA-MB-231 BRC cells were treated with various doses of DOX in culture and PD-L1
expression was quantified using qRT-PCR, flow cytometry, and western blot analysis. We also evaluated PD-L1 localization in HCT116
cells by immunofluorescence. Next, we assessed expression of miR-140 and miR-34a in DOX-treated HCT116 and MDA-MB-231
cells. Finally, we investigated whether miR-140 targets the 3’ UTR of the gene encoding PD-L1 in HCT116 cells using the p2FP-RNAi
RNAi reporter vector system. PD-L1 expression in HCT116 cells, while low at baseline, can be induced by treatment with 0.5 µM DOX.
MDA-MB-231 baseline PD-L1 expression exceeded HCT116 cell maximal expression and decreased following DOX treatment. We
further demonstrated that PD-L1 localizes to the cell surface in DOX-treated HCT116 cells. While miR-140 expression decreased in
DOX-treated HCT116 cells, it increased in DOX-treated MDA-MB-231 cells. MiR-34a expression increased in both DOX-treated cell
types. Finally, we present evidence for the regulation of PD-L1 by miR-140 in HCT116 cells. PD-L1 expression can increase following
treatment with DOX in HCT116 cells but decrease in MDA-MB-231 cells, suggesting a distinct response to DOX in these two different
cancer types. Also, a negative correlation between PD-L1 and miR-140 was observed in DOX-treated HCT116 cells, but not in MDAMB-231 cells.
Key words: PD-L1, doxorubicin, miR-34a, miR-140

1. Introduction
Colorectal cancer is reported as the leading cause of
cancer-related death worldwide (Torre et al., 2012). Most
patients with CRC are diagnosed in advanced stages,
where the main option for the treatment is chemotherapy
(Moertel et al., 1994). Chemotherapeutic drugs such as
5-fluorouracil and oxaliplatin are used in CRC treatment
despite their severe side effects like risk of infection,
anemia, and peripheral neuropathy (Midgley et al., 2005).
Therefore, alternative chemotherapeutic drugs would be
beneficial for patients.
Doxorubicin (DOX), which belongs to the
anthracycline family, is used for the treatment of various
cancer types including breast cancer, lung cancer, gastric
cancer, and leukemia, but not for CRC (Minotti et al.,
2004). Even though DOX in high doses has been shown to

be an efficient chemotherapeutic drug for the treatment of
advanced stage CRC, it is not the drug of choice because
high-dose treatment has side effects such as severe
cardiotoxicity (Ewer et al., 2015).
Programmed death ligand-1 (PD-L1, CD274, and B7H1), which is a transmembrane glycoprotein expressed
mainly on antigen presenting cells (APCs) and tumor cells,
inhibits activated T-cells by binding to their inhibitory
receptor, PD-1, in the tumor microenvironment (Tamura
et al., 2001; Selenko-Gebauer et al., 2003; Zang et al., 2007).
PD-L1 expression in multiple solid tumors, including
CRC, was shown to be associated with worse survival (Wu
et al., 2015). Recently developed immunotherapies, which
aim to block the PD-1/PD-L1 pathway using specific
monoclonal antibodies, dramatically improve antitumor
immune responses in various cancer types like skin cancer
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and non-small cell lung cancer (Zang and Allison, 2007;
Topalian et al., 2012). The PD-1/PD-L1 interaction was
shown to increase resistance of prostate and breast cancer
cells to DOX in vitro. Also, inhibition of PD-1/PD-L1
using antibodies against PD-1 improved the effect of DOX
to reduce metastasis in an in vivo model of breast cancer
(Black et al., 2016).
MicroRNAs (miRNAs) are short (20–22 nt)
noncoding RNAs that regulate gene expression at the
posttranscriptional level. Aberrant expression of miRNAs
is linked to many human disorders including cancer
(Volinia et al., 2006). PD-L1 expression is regulated by
various miRNAs in different cancer types (Wang et al.,
2017). miR-34a was reported to target PD-L1 in various
cancer cells including cells of osteosarcoma, acute myeloid
leukemia, and lung, breast, and colon cancer (Cortez et
al., 2015; Wang et al., 2015). Also, miR-140 targets PD-L1
in osteosarcoma and lung cancer (Ji et al., 2018; Xie et al.,
2018). DOX treatment can upregulate miR-140 expression
in osteosarcoma cells and miR-34a in lymphoma patients
(Wei et al., 2016; Zhu et al., 2017). These findings show
that control of PD-L1 expression may be complex and
tissue-specific. In this light, the effect of DOX on PD-L1
expression and microRNAs (miR-34a and miR-140) in
CRC cells has not been investigated.
Here, we evaluate the levels of PD-L1 and microRNAs
(miR-140-3p and miR-34a) expressions in DOX-treated
HCT116 colon cancer and MDA-MB-231 breast cancer
cell lines. We found that DOX treatment increased PDL1 expression in both the mRNA and protein levels in
HCT116 cells, but not in MDA-MB-231 cells. Also, we
demonstrate that miR-140-3p but not miR-34a expression
is downregulated in DOX-treated HCT116 cells, resulting
in increased PD-L1 expression.
2. Materials and methods
2.1. Cell culture
HCT116 cells were obtained from the ATCC (USA). MDAMB-231 cells were provided by Dr. Gizem Dinler Doğanay
(İstanbul Technical University, İstanbul, Turkey). Cells were
kept in DMEM medium (Lonza, Germany) including 10%
fetal calf serum (FCS) (Invitrogen Corp., UK), penicillin,
and streptomycin (Invitrogen Corp., UK). Cell lines were
assessed to evaluate mycoplasma contamination using the
Mycoplasma Detection Kit (Life Technologies). Cells were
maintained at 37 °C in a humidified 5% CO2 incubator.
2.2. Doxorubicin treatment
Twenty-four hours after seeding, cells were incubated with
different concentrations of DOX (Sigma-Aldrich, USA),
solubilized in DMSO, for 18 h.
2.3. Staining and flow cytometry
For surface staining, cells were stained with antihuman
CD274 (B7-H1, PD-L1)-APC (clone 29E.2A3) antibody
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(BioLegend, USA) in PBS containing 2% FCS for 1 h. Flow
acquisition was done with a BD Accuri C6 Cytometer
(Becton Dickenson, USA). Flow cytometric analyses were
performed using FlowJo Software (Tree Star, USA).
2.4. Western blot analysis
Cell pellets were lysed in a whole cell extract lysis (WCE)
buffer that includes 1 M HEPES, 0.4 mM NaCl, 25%
glycerol, 1 mM EDTA, 15 mM NaF, and 0.1% NP-40,
supplemented with protease inhibitors (Thermo Scientific)
and phosphatase inhibitors (Roche PhosSTOP) for 30 min
at 4 °C. Cell lysates were assayed for protein concentration
using the BCA protein assay (Thermo Fisher Scientific,
USA). Whole cell extracts were subjected to 10% SDSPAGE and transferred to nitrocellulose membranes for
immunoblotting. Ponceau S staining was performed to
validate efficient transfer. Membranes were placed together
with the following primary antibodies: antihuman PDL1 (1:100; clone 28-8, Abcam) and antihuman vinculin
(1:1000; clone EPR 8185, Abcam). Binding of primary
Abs was detected with HRP-conjugated antirabbit
(clone Ab 205718, Abcam) (1:1000). LumiGLO reagent
(Cell Signaling Technology) was used for enhanced
chemiluminescence detection. The blots were visualized
using a chemiluminescent western blotting detection
system (ChemiDoc MP imaging system; Bio-Rad) and
analyzed by Bio-Rad Image Lab software.
2.5. Immunofluorescence staining
HCT116 cells were plated on poly-L-lysine-coated
coverslips at 70% confluency. Cells were treated with 0.5
µM DOX for 18 h. After the treatment, samples were
placed in methanol for 20 min at –20 °C. Later, coverslips
were rinsed with PBS and incubated in blocking buffer for
30 min at RT and with primary mouse antihuman PDL1 antibody (1:50; clone 22C3, Dako) o/n at 4 °C. After
washing with PBS, coverslips were incubated together
with goat antimouse IgG (Alexa Fluor 594) secondary
antibody (1:100) (Cell Signaling Technologies) for 1 h
at RT. Coverslips were mounted in mounting medium
(VECTOR Laboratories Inc.). Image acquisition was
performed using a LSM 710 confocal microscope (Carl
Zeiss Micro Imaging) using the 405 nm and 561 nm laser
lines to excite DAPI and Alexa Fluor 594, respectively.
2.6. RNA extraction and q-RT-PCR
Total RNA was isolated from HCT116 and MDA-MB-231
cells using the Quick-RNA
Miniprep Plus Kit (Zymo Research). cDNA was
synthesized by a high-capacity cDNA synthesis kit (Applied
Biosystems). Q-RT-PCR was done on the ABI StepOnePlus
system (Applied Biosystems). 18S rRNA expression was
used for normalization of gene expression of each sample.
Mean relative gene expression was calculated. Also, the
differences were determined using the method of 2–ΔΔCT in
triplicate analyses. Primer sequences were PD-L1 forward
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5’- AAGACCACCACCACCAATTC -3’, reverse PD-L1
5’- CTGGGATGACCAATTCAGC -3’, 18S rRNA forward
5’-GGCCCTGTAATTGGAATGAGTC -3’, and reverse 5’
– CCAAGATCCAACTACGAGCTT- 3’.
For the expression analysis of miRNAs, total RNA
including miRNA was extracted using the Quick-RNA
Miniprep Plus Kit (Zymo Research, USA). Both cDNA
synthesis and miRNA amplification and detection
were performed using the EPIK miRNA Select Hi/
Lo-ROX Kit (Bioline, UK). The q-RT-PCR assay was
done by StepOnePlus Real-Time PCR System (Applied
Biosystems). The relative miRNA expression was calculated
through the comparative CT method. The CT value of
the target gene was normalized by the U6 housekeeping
reference. Primers for miR-140-3p (MIMAT0004597),
miR-34a-5p (MIMAT0000255), and the U6 housekeeping
gene (BIO66046) were purchased from Bioline (UK).
All reactions were performed in triplicate. Comparison
between DOX-treated and untreated cell lines was done
using the unpaired Student t-test (P < 0.05 significant).
2.7. miRNA mimics and reporter vector transfection
Reporter plasmids containing the PD-L1 gene 3’ UTR
(containing the miR140 target site) were generated by PCR
amplification of genomic DNA extracted from HCT-116
cells using the primers PDL-FWD: 5’-GGAAGATCTTCCAGCATTGGAACTTCTGATCTTC-3’
and
PDLREV:
5’-CCCAAGCTTTGCCTGGCACAGCGATTGATATTG-3’ containing restriction sites for the Bgl II
and Hind III restriction enzymes, respectively (bold letters). A PCR fragment of 1048 bp was digested with Bgl II
and Hind III and cloned into the same sites of the multiple
cloning site of the p2FP-RNAi dual color vector (Evrogen,
FP981) immediately after the coding region of the JRed
fluorescent protein gene.
2.8. Fluorescent miRNA activity assay
HCT116 cells were kept in DMEM with 10% FCS,
penicillin, and streptomycin. Cells were cultured 24
h before treatment at 40% confluency in 6-well plates
(300,000 cells/well). Prior to the transfection, growth
medium was changed with 2 mL of fresh medium. Cells
were transfected by preparing a mixture containing 2
µg of p2FP-RNAi plasmid DNA and 6 µL of 1 µg/µL
polyethyleneimine, linear, MW 25,000 (Polysciences,
23966) in 100 µL of medium without serum, antibiotics, or
phenol red. For assessing the activity of miRNA mimics,
a second mixture containing either 1 µL of nontargeting
mimic or miR-140 mimic and 6 µL of 1 µg/µL PEI in 100
µL of DMEM was simultaneously added to HCT116 cells.
Later, cells were analyzed by flow cytometry after 48 h.
Flow cytometry was performed on a FACS Fortessa flow
cytometer with appropriate filters to detect TurboGFP
fluorescence (excitation: 482 nm; emission: 538 nm) or
JRed fluorescence (excitation: 546 nm; emission: 607

nm) using 488 nm and 561 nm lasers to excite TurboGFP
and JRed, respectively. We calculated net fluorescence
by dividing the mean fluorescence of the empty p2FPRNAi plasmid transfected cells by that of PD-L1 3’ UTR
containing p2FP-RNAi plasmid-transfected cells. The
GFP mean fluorescence intensities of either control mimic
or miR-140 mimic expressing PD-L1 3’ UTR containing
p2FP-RNAi plasmid transfected cells were divided by their
JRed mean fluorescence intensity to calculate a GFP/JRed
mean ratio. Results are representative of two experiments.
2.9. Bioinformatics analysis
The TargetScan web server was used to predict target
miRNA binding to the 3’ UTR region of PD-L1.
2.10. Statistical analysis
Data are presented as mean ± SEM. Unless otherwise
stated, the unpaired Student t-test was used for
comparison. Graphs were prepared using GraphPad
Prism software. Pearson correlation was used to evaluate
potential correlation between miR-140-3p and PD-L1. P <
0.05 shows statistical significance.
3. Results
3.1. DOX induces PD-L1 expression in HCT116 colon
cancer cells
In order to examine whether doxorubicin has an effect
on PD-L1 expression in CRC cell lines, we treated the
HCT116 CRC cell line with 0.1, 0.5, and 1.5 µM DOX for
18 h. It was reported that DOX has a suppressive effect on
cell surface expression of PD-L1 in MDA-MB-231 cells
in a dose-dependent manner (Ghebeh et al., 2010). We
treated MDA-MB-231 cells with a dose (0.7 µM) of DOX
that was shown to cause 50%–60% decrease in surface PDL1 expression (Ghebeh et al., 2010). Next, we assessed both
mRNA and protein expression levels of PD-L1 in DOXtreated HCT116 and MDA-MB-231 cells. Interestingly, we
detected by qRT-PCR that 0.5 µM and to a lesser extent
1.5 µM, but not 0.1 µM DOX, induced PD-L1 mRNA
expression in HCT116 cells (Figure 1A). In contrast, PDL1 mRNA expression in MDA-MB-231 cells was reduced
significantly by DOX treatment, which confirmed the
findings in the literature (Figure 1A).
Next, we evaluated total PD-L1 protein levels in DOXtreated HCT116 and MDA-MB-231 cells by western
blotting. We selected DOX concentrations that led to an
effect on PD-L1 mRNA expression in HCT116 and MDAMB-231 cells, 0.5 µM and 0.7 µM doxorubicin, respectively.
PD-L1 has been reported to include four N-glycosylation
sites, three of which are related to stabilization (Li et al.,
2016). Therefore, there is a heterogeneous pattern of PDL1 on western blotting with glycosylated bands of about
40–50 kDa. The nonglycosylated PD-L1 is 33 KDa. While
DOX treatment resulted in increased PD-L1 protein
expression in HCT116 cells, it decreased in MDA-MB-231
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cells (Figures 1B and 1C). Overall, these data indicate that
DOX treatment affects BCC and CRC cells differently,
causing a decrease in MDA-MB-231 cells and an increase
of PD-L1 expression in HCT116 CRC cells both in RNA
and protein levels.
3.2. PD-L1 localizes to the cytoplasm and cell membrane
in DOX-treated HCT116 cells
Recent studies demonstrated that DOX downregulates
surface PD-L1 expression in MDA-MB-231 breast cancer
cells in a dose-dependent manner (Ghebeh et al., 2010). In
order to investigate the level of surface PD-L1 expression
in HCT116 and MDA-MB-231 cells, we treated these
cells with DOX for 18 h and analyzed surface expression
by flow cytometry. As expected, 0.7 µM DOX treatment
of MDA-MB-231 cells resulted in a significant decrease
in surface expression of PD-L1, which is consistent with
the previous literature (Figures 2A and 2B) (Ghebeh et al.,

2010). Strikingly, we found that 0.5 µM DOX treatment
caused a pronounced induction rather than a decrease of
surface PD-L1 expression in HCT116 cells. Also, 0.1 µM
DOX resulted in an increase of surface PD-L1 expression
in these cells. However, no significant induction of PD-L1
expression was shown in 1.5 µM DOX-treated HCT116
cells (Figures 2A and 2B).
Next, we evaluated the cellular localization and level
of PD-L1 expression in DOX-treated and nontreated
HCT116 cells by immunofluorescence. Previous studies
reported anomalous nuclear staining in DOX-treated
MDA-MB-231 cells (Ghebeh et al., 2010; Rom-Jurek et
al., 2018). In contrast, we found increased surface and
cytoplasmic, but not nuclear, localization of PD-L1 in
DOX-treated HCT116 cells (Figure 2C). Moreover, we
observed a pronounced increase of surface fluorescence
from anti-PD-L1 antibody staining upon 0.5 µM DOX

Figure 1. Doxorubicin regulates PD-L1 mRNA and protein in HCT116 and MDA-MB-231 cells in an opposite way. HCT116 and MDAMB-231 cells were incubated with various concentrations of doxorubicin (DOX) (for HCT116 cells (+) 0.1 µM, (++) 0.5 µM, (+++)
1.5 µM; for MDA-MB-231 cells (+) 0.7 µM) or without any treatment for 18 h. A) The mRNA expression of PD-L1 in DOX-treated or
nontreated HCT116 and MDA-MB-231 cells was assessed by qRT-PCR. Data are normalized to 18S rRNA and are representative of
3 independent experiments. P-values were calculated via unpaired t-test (**P < 0.01; ***P < 0.001). B) Protein expression of PD-L1 in
DOX-treated or nontreated HCT116 and MDA-MB-231 cells evaluated by immunoblotting. Vinculin was used as a loading control.
Immunoblots shown are representative of 3 independent experiments. n.s. denotes a nonspecific band. C) Densitometric quantification
of PD-L1 protein expression levels in DOX-treated and nontreated HCT116 and MDA-MB-231 cells was performed by normalizing to
vinculin.
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treatment in HCT116 cells (Figure 2C), which is consistent
with our western blot findings (Figures 1B and 1C).
3.3. An inverse correlation was detected between PDL1 expression with miR-140, but not with miR-34a, in
DOX-treated HCT116 cells
Recent reports indicated that PD-L1 is negatively regulated
by miR-34a in a p53- dependent manner in Nutlin-3 (p53
stabilizer)-treated HCT116 cells (Cortez et al., 2015). While
Nutlin-3 directly dissociates p53 from the ubiquitin ligase
MDM2 by competitive binding, doxorubicin is thought
to inhibit topoisomerase, result in DNA damage, and
activate the damage response pathway that results in the
phosphorylation of p53 and its dissociation from MDM2.
To identify whether DOX treatment can also regulate miR34a expression in HCT116 and MDA-MB-231 cells, we
assessed the levels of this miRNA by qRT-PCR. We found
a slight but significant increase of miR-34a expression in
DOX-treated HCT116 cells in a dose-dependent manner
compared with mock-treated cells (Figure 3A). In contrast,

there was a significantly higher expression of miR-34a in
DOX-treated MDA-MB-231 cells compared to HCT116
cells (Figure 3A). As we found that PD-L1 expression
decreased in DOX-treated MDA-MB-231 cells (Figure 1)
in which miR-34a expression was elevated (Figure 3A),
it might be possible that PD-L1 is regulated by miR-34a
in these cells. However, no inverse relationship between
PD-L1 expression and miR-34a expression was detected
in DOX-treated HCT116 cells. Therefore, another miRNA
might be responsible for PD-L1 regulation in DOX-treated
HCT116 cells.
In order to investigate potential miRNAs that might
target PD-L1, we performed bioinformatics analysis using
TargetScan (Xie et al., 2018). We observed that the PD-L1
mRNA’s 3’ UTR carries a putative miR-140 binding site at
position 43–49 (Figure 3B). This putative binding site does
not overlap with the previously identified binding site of
miR-34a (position 932–938) on PD-L1 mRNA (Cortez et
al., 2015). Next, we evaluated miR-140 expression in DOX-

Figure 2. PD-L1 surface expression was regulated conversely in HCT116 and MDA-MB-231 cells by doxorubicin treatment. A)
Representative histogram of surface expression of PD-L1 on HCT116 and MDA-MB-231 cells after treatment with different concentrations
of DOX (for HCT116 cells (+) 0.1 µM, (++) 0.5 µM, (+++) 1.5 µM; for MDA-MB-231 cells (+) 0.7 µM) for 18 h. B) Flow cytometric
measurement of three independent experiments are represented as MFI ratio = (MFIPD-L1/MFIunstained) ± SEM. Significance was calculated
using one-way analysis of variance (ANOVA). P-values are as follows: *P < 0.05; **P < 0.01. C) Representative immunofluorescence
image of HCT116 cells after 0.5 µM DOX treatment or kept untreated for 18 h. Anti-PD-L1 antibody is used to stain PD-L1 (green) and
DAPI (blue) is used to stain nucleus.
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treated HCT116 and MDA-MB 231 cells. We determined
that miR-140 expression was downregulated in DOXtreated HCT116 cells relative to the mock-treated control
in a dose-dependent manner (Figure 3C). On the contrary,
elevated miR-140 expression was detected in DOX-treated
MDA-MB-231 cells. Also, our analysis revealed an inverse
correlation between the miR-140 and PD-L1 expression in
DOX-treated HCT116 cells (Figure 3D). This may imply
that miR-140 has a role in regulation of PD-L1 in HCT116
cells. Thus, DOX treatment regulates expressions of PDL1 and miRNA-140 in opposite ways in the breast and
colorectal cell lines studied.
3.4. miR-140 partially regulates PD-L1 expression in
HCT116 cells
Because our findings suggested a negative correlation
between PD-L1 and miR-140, we assessed the presence

of functional miRNAs in HCT116 cells, which bind to the
3’ UTR region of PD-L1. For that reason, we transfected
HCT116 cells either with p2FP-RNAi plasmids that
included the 3’ UTR region of PD-L1 (p2FP-PD-L1
3’ UTR) or p2FP-RNAi-only control plasmids. The
p2FP-RNAi vector expresses two fluorescent proteins:
TurboGFP and JRed. Because the 3’ UTR region of PDL1 was cloned immediately following the TurboGFP gene,
GFP fluorescence serves as a reporter of 3’ UTR miRNA
activity, while JRed expression is used as a transfection
normalization control. If HCT116 cells contain functional
miRNAs targeting the PD-L1 3’ UTR, we expect decreased
TurboGFP expression with no reduction in JRed
expression. Indeed, we detected decreased TurboGFP
expression in p2FP-PD-L1 3’ UTR HCT116 cells when
compared to p2FP-RNAi plasmid-only transfected cells

Figure 3. Doxorubicin regulates miR-140 expression in HCT116 and MDA-MB-231 cells in an opposite way. HCT116 and MDAMB-231 cells were kept with various concentrations of DOX (for HCT116 cells (++) 0.5 µM, (+++) 1.5 µM; for MDA-MB-231 cells (+)
0.7 µM) or without any treatment for 18 h. A) The expression of miR-34a in DOX-treated or nontreated HCT116 and MDA-MB-231
cells assessed by qRT-PCR. B) Schematic image of PD-L1 and miRNA-140 interaction. C) The expression of miR-140 in DOX-treated or
nontreated HCT116 and MDA-MB-231 cells assessed by qRT-PCR. Data are normalized to U6 and are representative of 3 independent
experiments. P values were calculated by unpaired t-test (**P < 0.01; ***P < 0.001. D) The correlations of PD-L1 with miR-140 were
assessed. All values are expressed as means ± SEM. Data are normalized to U6. The data are representative of 3 independent experiments.
P values are calculated by unpaired t-test (*P < 0.05, **P < 0.01; ***P < 0.001, ****P < 0.0001).
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(Figures 4A and 4B). This result indicates that HCT116
cells contain functional miRNAs that regulate the PD-L1
3’ UTR.
Next, we asked whether miR-140 would regulate PDL1 expression in HCT116 cells. We transfected HCT116
cells with both p2FP-PD-L1 3’ UTR vectors and with
either control miRNA mimic or miRNa-140 mimic
RNA constructs. We determined that the miRNA-140
mimic slightly but significantly reduces gene expression
dependent on the PD-L1 3’ UTR region (Figures 4C and
4D). Overall, these experiments demonstrate that miR-140
can regulate PD-L1 gene expression in HCT116 cells.
4. Discussion
Doxorubicin (DOX), a member of the anthracyclines, is a
commonly used chemotherapeutic drug in the treatment
of solid tumors such as lung and breast cancer. However, its
usage in CRC treatment is limited due to chemoresistance
to the drug at low doses and cardiotoxic effects at high
doses of DOX (Ewer et al., 2015).
Chemotherapy has been shown to have immune
potentiating effects (Zitvogel et al., 2008). However, it is not
known whether immune response to chemotherapeutic
drugs is related to chemoresistance or chemosensitivity.

It is reported that human tumors express a coinhibitory
molecule, programmed cell death 1 ligand (PD-L1), at
rates of 19%–92% (Sznol et al., 2013). PD-L1, expressed
by cancer cells, binds to its receptors on T-cells and
downregulates T-cell function and proliferation (Park et
al., 2012). It is not clear how chemotherapeutic drugs affect
the PD-1/PD-L1 axis in the tumor microenvironment.
Earlier studies reported that DOX downregulates PD-L1
expression on the cell surface of MDA-MB-231 breast
cancer cells (Ghebeh et al., 2010). Because the DOX
effect on PD-L1 expression in CRC cells is not known,
we investigated the expression level of PD-L1 on DOX
treatment in HCT116 colon cancer cells. We found that
PD-L1 expression increased positively in DOX-treated
HCT116 colorectal cancer cells and decreased in MDAMB-231 breast cancer cells both in RNA and protein levels
(Figure 1). As PD-L1 expression is upregulated in DOXtreated CRC cells, it would be important to counteract
PD-L1 using a blockade of PD-1/PD-L1 in DOX-treated
CRC cells and evaluate whether this would increase the
drug efficiency. It was reported that PD-L1 localized to
the nucleus in DOX-treated MDA-MB-231 breast cancer
cells (Ghebeh et al., 2010). In contrast, we demonstrate
that PD-L1 is mainly localized on the surface and in the

Figure 4. miR-140 binds and partially regulates PD-L1 in HCT116 cells. HCT116 cells were kept untreated (dotted histogram) or
transfected either with p2FP-RNAi vector that included the 3’ UTR region of PD-L1 (p2FP-PD-L1 3’ UTR shaded histogram) or p2FPRNAi vector-only control (p2FP-RNAi-solid histogram). The p2FP-RNAi vector expresses two fluorescent proteins: TurboGFP and
JRed. A) Representative histogram of JRed and GFP expression in untreated, p2FP-RNAi, and p2FP-PD-L1 3’ UTR. B) Net expression of
JRed and GFP in groups shown in (A). C) HCT116 cells were kept untreated (-) or transfected with both p2FP-PD-L1 3’ UTR vector and
with either control miRNA mimic (Neg) or miRNA-140 mimic (miRNA-140). Representative contour plot that depicts the percentage
of GFP-positive cells. D) GFP/JRed mean ratio is shown for groups shown in (C). All values are expressed as means ± SEM. Significance
of the data was calculated using one-way analysis of variance (ANOVA). P values are as follows: *P < 0.05; **P < 0.01.
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cytoplasm, but not in the nucleus of DOX-treated HCT116
cells (Figure 2). We surmise that the discrepancy of PD-L1
localization in HCT116 and MDA-MB-231 cells may be
due to their distinct responses to DOX.
It was recently reported that miR-34a directly targets
and suppresses PD-L1 in breast cancer, lung cancer, colon
cancer, and acute myeloid leukemia (Wang et al., 2015;
Cortez et al., 2015). Concordantly, we found an increase of
miR-34a both in DOX-treated HCT116 and MDA-MB-231
cell lines with a higher expression in the latter. However,
there was only an inverse correlation between PD-L1
and miR-34a in DOX-treated MDA-MB-231 cells, not
in HCT116 cells (Figure 3). Also, miR-140 was shown to
target PD-L1 in lung and osteosarcoma cells (Ji et al., 2018;
Xie et al., 2018). We found that miR-140 was upregulated
in MDA-MB-231 cells and downregulated in HCT116 cells
(Figure 3). We demonstrate a novel negative correlation
between miR-140 and PD-L1 expression (r = –0.53, P <
0.025) in DOX-treated HCT116 colon cancer cells. Our
findings are in line with a recently published manuscript
showing an inverse correlation between miR-140 and PDL1 in lung cancer (Xie et al., 2018). To our knowledge, this
study is the first to show the effect of DOX on miR-34a
and miR-140 and the specific mechanism of PD-L1 gene
expression control in colon cancer cells. Additional studies
are necessary to determine the role of miR-140 in PD-L1
regulation of DOX-treated HCT116 cells.

Taken together, our findings identify a distinct effect of
DOX treatment on HCT116 colon cancer cells compared
to MDA-MB-231 breast cancer cells in regard to PD-L1
and miR-140 expression. These findings illuminate a path
toward future combined chemo- and immunotherapies
that aim to increase the efficiency of colorectal cancer
treatment. Such combination therapies could be formulated
with lower doses of doxorubicin, combined with antiPD-L1 antibody treatment, decreasing chemotherapy side
effects.
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